Science Fair Project Encyclopedia
|Chemical name||5-Hydroxy-tryptamine or|
|Molecular mass||176.22 g/mol|
The name "serotonin" is something of a misnomer and reflects the circumstances of the compound's discovery. It was initially identified as a vasoconstrictor substance in blood serum - hence "serotonin", a serum agent affecting vascular tone. This agent was later chemically identified as 5-hydroxytryptamine (5-HT) and as the broad range of physiological roles were elucidated, 5-HT became the preferred name in the pharmacological field.
Serotonin is found extensively in the human gut, as well as in the blood stream.
Serotonin taken orally does not pass into the serotonergic pathways of the central nervous system (CNS). This is due to the blood-brain barrier preventing serotonin in the blood stream from affecting serotonin levels in the brain. However, the amino acid tryptophan and its metabolite 5-hydroxytryptophan, from which serotonin is synthesized, are capable of crossing the blood-brain barrier. These agents are available as dietary supplements and may be effective serotonergic agents, though their efficacy is questionable.
5-HT is released from the terminal boutons (buttons) of serotonergic neurons into the neuronal synapse. In the synapse it is free to diffuse across to and activate 5-HT receptors located on the dendrites of adjacent neurons.
Serotonergic action is terminated primarily via uptake of 5-HT from the synapse. This is through the specific monoamine transporter for 5-HT, 5-HT reuptake transporter, on the presynaptic neuron. Various agents can inhibit 5-HT reuptake including MDMA, cocaine, tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs).
The pharmacology of 5-HT is extremely complex, with its actions being mediated by a large and diverse range of 5-HT receptors.
Modulating levels of 5-HT
A variety of psychiatric medications affect serotonin levels, including the monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and the selective serotonin reuptake inhibitors (SSRIs).
The MAOIs prevent the breakdown of monoamine neurotransmitters (including serotonin) and therefore increase concentrations of the neurotransmitter in the brain. MAOI therapy is associated with many adverse drug reactions and patients are at risk of hypertensive crisis triggered by foods with high tyramine-content and certain drugs.
Some drugs inhibit this re-uptake of serotonin, again making it stay in the synapse longer. The tricyclic antidepressants inhibit the re-uptake of both serotonin and norepinephrine. The newer Selective Serotonin Re-uptake Inhibitors (SSRIs) have fewer (though still numerous) side effects and fewer interactions with other drugs.
Care must be taken in any attempt to increase serotonin levels, as a dangerous condition known as serotonin syndrome may result. This is especially a concern if multiple serotonergic agents interact to increase 5-HT levels - such as can happen when St Johns Wort is taken in combination with an SSRI.
- Rang HP, Dale MM, Ritter JM, Moore PK (2003). Pharmacology (5 ed). Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4
The contents of this article is licensed from www.wikipedia.org under the GNU Free Documentation License. Click here to see the transparent copy and copyright details